Browsed by
Tag: interview

U.S. Transhumanist Party Interview with Bobby Ridge

U.S. Transhumanist Party Interview with Bobby Ridge

The New Renaissance Hat
Gennady Stolyarov II and Bobby Ridge
July 8, 2017
******************************

 


Gennady Stolyarov II, Chairman of the United States Transhumanist Party, interviews Bobby Ridge, a researcher into transhumanist philosophy and the scientific method and the new Secretary-Treasurer of the United States and Nevada Transhumanist Parties.

Watch this conversation regarding the subjects of Mr. Ridge’s research, the scientific method, and transhumanism more generally.

Bobby Ridge has a Bachelor’s Degree in Biomedical Science from California State University of Sacramento (CSUS) and is striving to achieve his MD in Neurology. He only recently became a Transhumanist. He conducts research for CSUS’s Psychology Department and his own personal research on the epistemology and Scientiometrics of the Scientific Method. He also co-owns Togo’s in Citrus Heights, CA. Mr. Ridge considers transhumanism to describe the future of humanity taking its next steps in evolution, which are both puissant and daunting. With the exponential increase in information technology, Mr. Ridge considers it important for us to become a science-based species to prevent a dystopian-type future from occurring.

Visit the website of the U.S. Transhumanist Party at http://transhumanist-party.org/.

Become a member of the U.S. Transhumanist Party for free by filling out this form.

U.S. Transhumanist Party Interview with Kevin Baugh, President of Molossia

U.S. Transhumanist Party Interview with Kevin Baugh, President of Molossia

The New Renaissance Hat
G. Stolyarov II
******************************

To celebrate Founders’ Day – the 40th anniversary of the founding of the Republic of Molossia – representatives of the U.S. and Nevada Transhumanist Parties made an international trip on May 27, 2017, to join President Kevin Baugh in his micronation.

Gennady Stolyarov II, Chairman of the U.S. Transhumanist Party, interviewed President Baugh on what attributes are needed to form a successful, long-lasting micronation, how micronationalism can inform our understanding of politics, countries, and governments, and how technology is essential to the development of micronations. Both micronationalism and technology have the potential to bring people closer together in terms of finding others who share similar interests and goals.

This speech by President Baugh provides background into the founding of Molossia and the concept behind it, as well as the ambitions for its future as a leading micronation of the world.

Find out about the Republic of Molossia here and read its Wikipedia entry here.

Visit the U.S. Transhumanist Party website here.

Become a member of the U.S. Transhumanist Party for free here.

Section XXII of the U.S. Transhumanist Party Platform reads: “The United States Transhumanist Party supports efforts at political, economic, and cultural experimentation in the form of seasteads and micronations. Specifically, the United States Transhumanist Party recognizes the existence and sovereignty of the Principality of Sealand, the Republic of Molossia, and the Free Republic of Liberland, and supports the recognition of these entities by all governments and political parties of the world.”

U.S. Transhumanist Party Interview with Travis McHenry, Grand Duke of Westarctica

U.S. Transhumanist Party Interview with Travis McHenry, Grand Duke of Westarctica

The New Renaissance Hat
G. Stolyarov II
******************************

Gennady Stolyarov II, Chairman of the U.S. Transhumanist Party, interviews Grand Duke Travis McHenry of Westarctica on the attributes needed to form a long-lasting micronation, the role of technology in enabling more micronations to form over time, and what micronationalism can teach us about politics and organizational leadership.

Find out about Westartica here and read its Wikipedia entry here.

Visit the U.S. Transhumanist Party website here.

Become a member of the U.S. Transhumanist Party for free here.

Section XXII of the U.S. Transhumanist Party Platform reads: “The United States Transhumanist Party supports efforts at political, economic, and cultural experimentation in the form of seasteads and micronations. Specifically, the United States Transhumanist Party recognizes the existence and sovereignty of the Principality of Sealand, the Republic of Molossia, and the Free Republic of Liberland, and supports the recognition of these entities by all governments and political parties of the world.”

In the spirit of this plank, the U.S. Transhumanist Party also recognizes the nation of Westarctica and the efforts of Grand Duke Travis to eventually render its territory suitable for human habitation.

Nevada Transhumanist Party Interview on the EMG Radio Show – November 7, 2016

Nevada Transhumanist Party Interview on the EMG Radio Show – November 7, 2016

The New Renaissance HatG. Stolyarov II
******************************

On November 7, 2016, Mr. Stolyarov had his first radio interview as Chief Executive of the Nevada Transhumanist Party. The EMG Radio Show on 91.5 The Rebel HD-2, hosted by Andre’ Haynes, interviewed Mr. Stolyarov for about 10 minutes on the mission of the Nevada Transhumanist Party and transhumanist views on emerging technologies – such as artificial wombs, designer babies, artificial intelligence, and life extension.

The interview begins at 2:00 in the video.

This recording was reproduced with permission from the EMG Radio Show.

Download the interview recording here.

Visit the Nevada Transhumanist Party page here.

Join the Nevada Transhumanist Party Facebook group here.

Find out about Mr. Stolyarov here.

NTP-Logo-9-1-2015

An Interview with Kelsey Moody of Ichor Therapeutics, Bringing a SENS Therapy for Macular Degeneration to the Clinic – Article by Reason

An Interview with Kelsey Moody of Ichor Therapeutics, Bringing a SENS Therapy for Macular Degeneration to the Clinic – Article by Reason

The New Renaissance HatReason
******************************

As I mentioned last week, earlier this year Fight Aging! invested a modest amount in the Ichor Therapeutics initiative to develop a treatment for macular degeneration, joining a number of other amateur and professional investors in helping to get this venture started. The approach taken here is based on the results of research carried out at the Methuselah Foundation and SENS Research Foundation over much of the past decade, funded by philanthropists and the support of our community of longevity science enthusiasts. This is how we succeed in building the future: medical science in the laboratory leads to medical development in startup companies, each new stage bringing treatments capable of repairing specific forms of age-related molecular damage that much closer to the clinic.

Ichor Therapeutics is one of a growing number of success stories to emerge from the SENS rejuvenation research community. Young scientists, advocates, and donors involved in earlier projects – years ago now – have gone on to build their own ventures, while retaining an interest in stepping up to do something meaningful to help bring an end to aging. Back in 2010, Kelsey Moody worked on the LysoSENS project to find ways to break down damaging metabolic waste in old tissues; fast-forward six years, and he is the now the CEO of a successful small biotechnology company with a great team, taking that very same technology and putting it to good use. I recently had the chance to ask Kelsey a few questions about the future of SENS rejuvenation research, as well as how the Ichor scientists intend to construct a new class of therapy for macular degeneration, one based on removing one of the root causes of the condition.

Quote:

Who are the people behind Ichor Therapeutics? How did you meet and decide that this was the thing to do? Why macular degeneration as a target?

People have always been the focus of Ichor. Since day one we have worked to create a positive environment that cultivates a product-oriented research focus and emphasizes autonomy and personal accountability for work. As a result, ambitious self-starters tend to find their way to Ichor and remain here. However, we recognized early on that just filling a lab with a bunch of blue-eyed bushy tailed young up-and-comers is not sufficient to develop a robust, mature, translational pipeline. We have augmented our team with a number of critical staff members who are seasoned pharma operators, including our Quality Assurance Director and General Counsel.

Age-related macular degeneration (AMD) was chosen as a target because we believe it is the closest SENS therapy to the clinic. While we obviously have an interest in providing cures for the patients suffering from AMD and are attracted to the large market opportunities such a treatment could bring, our broader interest is in validating the entire SENS paradigm. We believe that Aubrey de Grey continues to receive excessive criticism because nothing spun out of SENS has ever made it into a legitimate pre-clinical pipeline, much less to the bedside. However, this does not mean he is wrong. Our goal is to be the first group to bring a SENS inspired therapy into the clinic and in doing so, silence critics and generate new energy and capital for this cause.

I understand there’s a lengthy origin story for the approach you are taking to treat AMD; it’d be great to hear some of it.

Our approach to treating AMD is based on the hypothesis that cellular junk that accumulates over the lifespan significantly contributes to the onset and progression of AMD. Our goal is to periodically reduce the burden of the junk so it never accumulates to levels sufficient to induce pathology. The strategy to accomplish this calls for the identification of enzymes that can break down the junk in a physiological setting, and the engineering of these enzymes such that they can break down the target in the correct organelle of the correct cell without appreciable collateral damage to healthy cells or tissue.

Methuselah Foundation and SENS Research Foundation did excellent work in establishing this program nearly a decade ago. They successfully identified a number of candidate enzymes that could break down the molecular junk, but reported that the targeting systems evaluated failed to deliver these enzymes to the appropriate organelles and cells. My group reevaluated these findings, and discovered that these findings were flawed. The delivery failure could be entirely attributed to a subtle, yet highly significant difference between how the target cells behave outside of the body as compared to inside the body. It turned out that the approach was in fact valid, it was the cell based assay that had been used that was flawed. This discovery was striking enough that SENS Research Foundation provided Ichor with funding and a material and technology transfer agreement to reassess the technology, and over $700,000 in directed program investments and grants have been received in the last year or two.

You recently completed a round of funding for the AMD work; what is the plan for the next year or so?

The new funds will allow us to develop a portfolio of enzyme therapy candidates to treat AMD. We will obtain critical data necessary to secure follow-on investment including in vitro studies (cell culture studies to confirm mechanism of action and cytotoxicity) and pivotal proof-of-concept in vivo studies, such as toxicity, PK/PD (how long the enzyme stays in the body and where), and efficacy. We will also be restructuring the company (reincorporating an IP holding company in Delaware, ensuring all contracts are up to date and audited) and ensuring our IP position is on solid footing (licensing in several related patents from existing collaborators, and filing several provisional patents from our intramural work). Collectively, we believe these efforts will position us to obtain series A for investigational new drug (IND) enabling pre-clinical studies.

You’ve been involved in the rejuvenation research community for quite some time now. What is your take on the bigger picture of SENS and the goal of ending aging?

This is a loaded question. What I can say is that the medical establishment has made great progress in the treatment of infectious disease through the development of antibiotics, vaccines, and hygiene programs. However, similar progress has not been realized for the diseases of old age, despite exorbitant expenditures. I have chosen to work in this space because I think a different approach is necessary, and it is here that I believe my companies and I can be the most impactful. I think SENS provides a good framework within which to ask and answer questions.

What do you see as the best approach to getting nascent SENS technologies like this one out of the laboratory and into the clinic?

We need more people who fully understand, in a highly detailed way, what a real translational path looks like. To take on projects like this, being a good scientist is not enough. We need people who can speak business, science, medicine, and legal, and apply these diverse disciplines to a well articulated, focused product or problem. There is no shortage of people who partially understand some of these, but the details are not somewhat important – they are all that matter for success in this space.

Another area is for investors. Some of the projects that come across my desk for review are truly abysmal, yet I have seen projects that are clearly elaborate hoaxes or outright scams (to anyone who has stepped foot in a laboratory) get funded to the tune of hundreds of thousands of dollars or more. While it is perfectly reasonable for high net worth individuals to gamble on moon shots in the anti-aging space (and I am ever grateful for the investors who have taken such a gamble on us) even aggressive development strategies should have some basis in reality. This is especially true as more and more high tech and internet investors move into the space.

If this works stupendously well, what comes next for Ichor Therapeutics?

I really want to get back into stem-cell research, but I basically need a blank check and a strong knowledge of the regulatory path to clinic before I feel comfortable moving into the space. A successful AMD exit would accomplish both of these goals, and position us to pivot to cell-based therapies.

Reason is the founder of The Longevity Meme (now Fight Aging!). He saw the need for The Longevity Meme in late 2000, after spending a number of years searching for the most useful contribution he could make to the future of healthy life extension. When not advancing the Longevity Meme or Fight Aging!, Reason works as a technologist in a variety of industries.
***
This work is reproduced here in accord with a Creative Commons Attribution license. It was originally published on FightAging.org.
G. Stolyarov II Interviews Demian Zivkovic Regarding the D.N.A. – Gene Therapies Congress

G. Stolyarov II Interviews Demian Zivkovic Regarding the D.N.A. – Gene Therapies Congress

The New Renaissance Hat
G. Stolyarov II and Demian Zivkovic
******************************

Mr. Stolyarov invited Demian Zivkovic, President of the Institute of Exponential Sciences (IES), to discuss the forthcoming Designing New Advances (D.N.A.) Gene Therapies Congress in Utrecht, The Netherlands.

The interview took place on Sunday, June 19, 2016, at 11 a.m. US Pacific Time. Watch the recording here.

The D.N.A. Congress is scheduled to occur on July 9, 2016, and will feature speakers such as Oliver Medvedik, Aubrey de Grey, Elizabeth Parrish, Keith Comito, and Tatjana Kochetkova. This event receives the strong endorsement of both The Rational Argumentator and the Nevada Transhumanist Party.

Read the announcement of the D. N. A. Congress here.

Contribute to the fundraiser for the D. N. A. Congress on Indiegogo  and Generosity.

DNA_Interview_CoverDemian Zivkovic is the president of the Institute of Exponential Sciences  (Facebook  / Meetup) – an international transhumanist think tank / education institute comprised of a group of transhumanism-oriented scientists, professionals, students, journalists, and entrepreneurs interested in the interdisciplinary approach to advancing exponential technologies and promoting techno-positive thought. He is also an entrepreneur and student of artificial intelligence and innovation sciences and management at the University of Utrecht.

Demian and the IES have been involved in several endeavors, such as organizing lectures on exponential sciences, interviewing experts such as Aubrey de Grey, joining several of Mr. Stolyarov’s futurism panels, and spreading Death is Wrong – Mr. Stolyarov’s illustrated children’s book on indefinite life extension – in The Netherlands.

Demian Zivkovic is a strong proponent of healthy life extension and cognitive augmentation. His interests include hyperreality, morphological freedom advocacy, postgenderism, and hypermodernism. He is currently working on his ambition of raising enough capital to make a real difference in life extension and transhumanist thought.

Third Interview of Gennady Stolyarov II and Wendy Stolyarov by Roen Horn of the Eternal Life Fan Club – May 2, 2015

Third Interview of Gennady Stolyarov II and Wendy Stolyarov by Roen Horn of the Eternal Life Fan Club – May 2, 2015

The New Renaissance Hat
G. Stolyarov II and Wendy Stolyarov
September 6, 2015
******************************

ELFC_DIW_Third_InterviewNote by Mr. Stolyarov: On May 2, 2015, a hot spring day in Roseville, California, Wendy Stolyarov and I visited Roen Horn of the Eternal Life Fan Club and had a lengthy discussion with him on a wide variety of subjects: life extension, our illustrated children’s book Death is Wrong, healthcare policy, criminal punishment, and the political prospects of the Transhumanist Party and third parties in general. This was Roen’s third interview with us (watch the first and second interviews as well), and his skillfully edited recording offers a glimpse into its best segments. This conversation occurred approximately four months before Wendy and I took the step to found the Nevada Transhumanist Party, but my comments in this interview are a good example of the evolution of my thinking in this direction, as I was already inclined toward endorsing Zoltan Istvan’s 2016 Presidential run.

Watch the interview here.

Join the Nevada Transhumanist Party here.

G. Stolyarov II Interviews Adam Alonzi Regarding Emerging Biotech Research

G. Stolyarov II Interviews Adam Alonzi Regarding Emerging Biotech Research

The New Renaissance Hat
G. Stolyarov II and Adam Alonzi
August 28, 2015
******************************

On August 23, 2015, Mr. Stolyarov invited Adam Alonzi to share the insights he was able to glean from many recent discussions with biotechnology entrepreneurs and researchers. Mr. Alonzi was able to subsequently edit some of his remarks to remedy the technical issues with audio quality during the broadcast. His edited version appears below.

See the original interview recording:

Adam Alonzi is the author of Praying for Death and A Plank in Reason. He is also a futurist, inventor, DIY enthusiast, biotechnologist, programmer, molecular gastronomist, consummate dilletante and columnist at The Indian Economist. Read his blog here. Listen to his podcasts at http://adamalonzi.libsyn.com.

Adam Alonzi’s Interviews
Elizabeth Parrish – BioViva
Alex Zhavoroknov – InSilico Medicine
Maria Konovalenko – Science for Life Extension Foundation and Longevity Cookbook
Luis Arana – Robots Without Borders

Second Interview of Gennady Stolyarov II and Wendy Stolyarov by Roen Horn of the Eternal Life Fan Club – November 27, 2014

Second Interview of Gennady Stolyarov II and Wendy Stolyarov by Roen Horn of the Eternal Life Fan Club – November 27, 2014

The New Renaissance Hat
G. Stolyarov II and Wendy Stolyarov II
November 27, 2014
******************************
ELFC_DIW_Second_Interview
 

Today Wendy Stolyarov and I had an excellent second interview and conversation with Roen Horn of the Eternal Life Fan Club. We discussed our recent activities related to the life-extension movement, the impact of “Death is Wrong”, and many philosophical and practical ideas surrounding the pursuit of indefinite longevity.

Watch the recorded interview here.

The Continued Momentum of “Death is Wrong” in August-September 2014 – Post by G. Stolyarov II

The Continued Momentum of “Death is Wrong” in August-September 2014 – Post by G. Stolyarov II

The New Renaissance Hat
G. Stolyarov II
September 25, 2014
******************************

GSII_Age_5_QuoteI am pleased to report that, through late August and September 2014, the momentum of Death is Wrong has continued.

An excellent and entertaining recent interview of me was done by Leonardo Nunes Ricucci on La República Democrática de Leo, where we discussed Death is Wrong, transhumanism, indefinite life extension, risk management, and related topics. You can listen to the podcast and download an MP3 file of the episode here.

On September 6, 2014, Roen Horn of the Eternal Life Fan Club interviewed Wendy and me about Death is Wrong and related arguments for life extension and technological progress. The interview was extensive, and many subjects were discussed. Watch it here.

Here is the video trailer that was posted two days in advance of the interview.

Roen has been doing excellent work in recording his Death is Wrong book giveaways on video. Here is a quick video of his second giveaway of a book to a family with four children.

The book has continued to play a role in discussions of longevity and future remedies to the ravages of senescence. Here is a great post by Will Muessig of Unity Politics, mentioning Death is Wrong and refuting Ezekiel Emanuel’s deeply fallacious recent article about why age 75 is a good age to die.

I am also pleased to have had my thoughts included in “Cyborgs: The truth about human augmentation” – an excellent new article by Frank Swain on BBC Future. Mr. Swain had previously interviewed me about Death is Wrong, which led to his article “How to live forever” being published by BBC Future in April 2014. This time Mr. Swain asked me to help debunk common myths about human augmentation, and was happy to share my vision of “a future in which a thousand augmented flowers bloom” and in which augmentations will help people live longer, more fulfilling lives as well.

The continued infusion of the ideas of indefinite life extension into publicly prominent discussions was one of my key aims in writing Death is Wrong. Just like our book-distribution campaign, this aim is being fulfilled right now, and it will hopefully keep paying cultural dividends to the longevity movement for months and years to come.